Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2025—A retired pathologist believes pathologists should be more involved in gross examination of specimens, not just microscopic analysis. A pathologist praises the Canadian series “Coroner” for its realistic portrayal of the forensic pathology world, crediting the involvement of a real forensic pathologist as a consultant.
January 2026—The CAP president emphasizes the importance of inspiring others in the field of pathology. This can be achieved by encouraging new voices to join the field, engaging with medical students, and actively participating in the CAP.
January 2026—Federally qualified health centers (FQHCs) in Illinois demonstrated higher guideline adherence for kidney disease testing compared to non-FQHCs. Patients with low eGFR or diabetes at FQHCs were more likely to receive recommended uACR and dual testing, respectively.
January 2026—Ossifying fibromyxoid tumors with lipomatous and cartilaginous differentiation are rare mesenchymal neoplasms that can be challenging to diagnose. A study identified six cases with these features, expanding the tumor’s known histomorphological spectrum.
January 2025—TITAN, a multimodal whole slide foundation model, outperforms existing slide encoders in various diagnostic and prognostic tasks, including rare disease classification. While promising, TITAN’s limitations, such as partial image representation and domain shift, necessitate further validation and workflow integration before clinical use.
January 2026—Two studies investigated the use of DNA methylation patterns and sex-specific gene expression in neuroendocrine neoplasms (NEN) and Alzheimer disease, respectively.
January 2026—The CAP Council on Informatics and Pathology Innovation (CIPI) launched the CIPI Connections podcast, focusing on informatics in pathology. The podcast, featuring episodes on various topics, aims to educate and introduce listeners to pathology innovators and thought leaders.
January 2026
Q. What is the CAP’s stance on antibody identification software, which is available via subscription, middleware, or an open-source platform? Read answer.
Q. Can toxicology testing be performed on a person who has been deceased for two years? Read answer.
January 2026—The CAP released a guideline for amyloidosis lab workup, recommending Congo red staining for amyloid detection and mass spectrometry for fibril protein typing. The guideline emphasizes the importance of accurate and timely identification of amyloid fibril types for effective treatment.
